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ABSTRACT
Aims/Introduction: We assessed the tolerability, effectiveness and predictive parame-
ters for the therapeutic usefulness of exenatide in obese Korean participants with type 2
diabetes. We also evaluated the characteristics of participants who respond adequately to
glucagon-like peptide-1 (GLP-1) analog therapy in terms of glycated hemoglobin (HbA1c)
level reductions and weight loss.
Materials and Methods: This prospective, observational, single-arm (exenatide b.i.d. in
combination with both metformin and sulphonylurea), open-label study of GLP-1 analog
treatment with close monitoring of metabolic parameters and weight changes was carried
out for up to 22 weeks.
Results: Of the 110 enrolled obese participants, 37 participants dropped out during the
22-week treatment period. A total of 73 participants completed the study (median age
55.0 years, interquartile range 44.0–65.0). The median duration of diabetes was 8.0 years
(interquartile range 3.5–12.5) with a mean HbA1c value of 7.6% (interquartile range
7.00–8.55). The median body mass index was 30.78 kg/m2 (interquartile range
27.89–33.92). After 22 weeks, median changes from baseline for HbA1c levels and weight
were -0.7% and -3.0 kg, respectively, which were significant. No severe hypoglycemic
events were observed. Multivariate regression analysis showed that C-peptide values were
a significant independent predictor for a reduction in HbA1c levels (b = 0.865, P = 0.018)
with exenatide BID in combination with both sulphonylurea and metformin in obese
Korean participants with type 2 diabetes and insulin na€ıvete.
Conclusions: Clinical and laboratory parameters, such as insulin na€ıvete and preserved
b-cell function, should be taken into consideration as important factors in the choice of
GLP-1 analog when predicting GLP-1 analog responsiveness. This trial was registered with
the local committee at Yonsei University in Korea (4-2011-0032).
INTRODUCTION
Under normal glucose or type 2 diabetes conditions, glucose
status is mainly inﬂuenced by the pathophysiological nature of
dysfunctional pancreatic b-cells and increased peripheral insulin
resistance1,2. Because insulin resistance is signiﬁcantly associated
with obesity, the risks of developing and aggravating diabetes
are in parallel to the degree of excess bodyweight3. Until the
advent of incretin-based therapy, metformin had been the only
glucose-lowering drug that could bring about weight loss in
diabetic patients. Glucagon-like peptide-1 (GLP-1) analog,
which has shown plenty of evidence of reducing HbA1c levelsReceived 18 October 2012; revised 3 September 2013; accepted 24 October 2013
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and bodyweight, has been gaining popularity for its potential
pleiotropic effects on cardiovascular disorders, as well as for
treatment of type 2 diabetes by modulating multiple gluco-
regulatory actions, such as increasing insulin secretion in
response to glucose levels, suppressing hepatic glucagon action,
increasing satiety and so on4,5. Despite this beneﬁcial evidence,
GLP-1 analog has the inherent problems of needle injection
and gastrointestinal adverse effects, such as nausea, vomiting
and diarrhoea. In this regard, balancing the beneﬁcial and
adverse effects of GLP-1 analog might be essential for the
practical prescription of GLP-1 analog in patients with type 2
diabetes.
However, clinical reports on the clinical efﬁcacy and adverse
effects of GLP-1 analog in the Korean population are greatly
lacking. Furthermore, there is no report regarding the charac-
teristics of patients who respond adequately to GLP-1 analog
therapy in terms of glycated hemoglobin (HbA1c) level reduc-
tions and weight loss. Therefore, we analyzed the clinical and
metabolic parameters in obese type 2 diabetic patients to char-
acterize patients who are more likely to achieve not only gly-
caemic reduction, but also weight loss.
METHODS
The present prospective, observational, single-arm (exenatide
b.i.d. in combination with both metformin and sulphonylurea
[SU]), open-label study of GLP-1 analog treatment with close
monitoring of metabolic parameters and weight changes was
carried out for up to 22 weeks. The study protocol was
reviewed by the local ethics committees (4-2011-0032). All of
the participants provided written informed consent, and the
study was carried out in accordance with the principles of the
Declaration of Helsinki. Inclusion criteria were: patients with
type 2 diabetes who were obese (>25 kg/m2) aged 25–75 years
with inadequate glycemic control (deﬁned as HbA1c ≥6.5%
and ≤10%) on any oral hypoglycemic agents or insulin ana-
logs treatment. We included patients with unchanged treat-
ment regimen for at least 6 months before starting the study.
Patients were excluded if they had a recent (≤6 months) sig-
niﬁcant history of cardiovascular events, including myocardial
infarction, unstable angina, moderate to severe congestive
heart failure and/or stroke. In addition, patients with a signiﬁ-
cant history or the presence of hepatic, renal, hematological or
gastrointestinal disease, or treatment with a systemic cortico-
steroid in the past 12 weeks were excluded. Patients received
exenatide 5 lg b.i.d. for the ﬁrst 4 weeks, followed by 10 lg
b.i.d. for the remaining 18 weeks while continuing their pre-
study metformin and SU dosages; however, previous pioglitaz-
one, a-glucosidase inhibitor, dipeptidyl peptidase 4 (DPP-4)
inhibitor and insulin regimens were discontinued. When exe-
natide was initiated, we changed the regimens to follow the
Korean medical insurance reimbursement guideline as
described in Methods S1 (Drug Switching Protocol). Clinic
visits initially occurred at 8-week intervals, and then at 14-
week intervals for the remainder of the study. If HbA1c levels
were at or above 7.5% at the ﬁrst visit after study enrolment,
the SU dosage was escalated up to 8 mg of glimepiride and
120 mg gliclazide-modiﬁed release. Laboratory measurement
and homeostasis model assessment (HOMA) index calculation
was followed as described in Methods S1 (Laboratory Mea-
surements).
Effectiveness Assessments
The primary end-point was the change in HbA1c levels and
bodyweight from baseline to week 8 and week 22. Other end-
points included fasting plasma glucose (FPG) and fasting lipid
concentrations (low-density lipoprotein cholesterol, high-density
lipoprotein cholesterol, total cholesterol and triglycerides).
HbA1c responders (marked as HbA1c[+]) were deﬁned as
those who showed negative delta HbA1c values, and weight
responders (marked as Wt[+]) were deﬁned as those who
showed negative delta bodyweight over 22 weeks of exenatide
treatment. Participants who completed the study were classiﬁed
into three groups according to their reduction in HbA1c level
and weight: reduction in both HbA1c level and weight (group I),
only HbA1c level reduction (group II) and only weight loss
(group III).
Tolerability and Hypoglycemia Assessments
Reasons for discontinuation of the study and treatment-induced
adverse events were recorded to assess tolerability and compli-
ance. Monitoring of adverse events, including hypoglycemia,
was surveyed by clinical coordination of the Lilly Call Center
once a week for 8 weeks, and was voluntarily reported by the
participants. In addition, the endocrinologists carried out sur-
veys about the patients’ conditions in outpatient clinics during
the scheduled visits. A hypoglycemic event was deﬁned as a
major episode that required treatment or admission (deﬁned by
blood glucose ≤60 mg/dL accompanied by neurological symp-
toms consistent with hypoglycemia or an episode requiring
intervention with intravenous glucose).
Statistical Analysis
All statistical analyses were carried out with PASW statistics soft-
ware (version 18.0; SPSS Inc., Chicago, IL, USA). Continuous
variables with non-normal distributions were expressed as
medians (interquartile range [IQR]). Discrete variables were
expressed as percentages using the v2-test. Statistical compari-
sons among groups based on HbA1c level and weight reduc-
tion were carried out using the Kruskal–Wallis test. We carried
out Friedman’s test to detect differences in repeatedly measured
variables. Spearman’s correlation coefﬁcient was used to deter-
mine the relationship between HbA1c level and bodyweight
changes, and the continuous variables. Multivariate regression
analysis was used to estimate multiple correlations between
HbA1c levels or weight changes, and clinical and laboratory
risk factors. A variance inﬂation factor >10 suggests an errone-
ous model, and was not included in the models. Data with a
P-value <0.05 were considered signiﬁcant.
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RESULTS
Baseline Clinical and Laboratory Participant Characteristics and
Tolerability of Exenatide
Of the total of 110 intent-to-treat (ITT) participants who
received more than a one-time injection of exenatide b.i.d., 73
participants completed and 37 participants failed to complete
the 22-week study (Figure 1). Among the 37 participants who
dropped out of the study, 10 and 25 participants discontinued
the exenatide within 4 weeks and 5–8 weeks, respectively. After
the ﬁrst follow-up visit, two participants additionally dropped
out due to incompatibility with their time schedule or labora-
tory examinations. The most frequent reasons for discontinua-
tion were: gastrointestinal adverse effects (AEs), such as nausea,
vomiting and diarrhoea (12 participants [36.4%]); reluctance to
have injections (7 participants [21.2%]); weight gain (2 partici-
pants [6.1%]); and uncontrolled hyperglycaemia (1 participant
[3.0%]). Nine participants (27.3%) did not provide a reason for
discontinuing the study. Table S1 shows the clinical and labora-
tory data of the 73 participants who completed the study (22
men and 51 women) and 37 participants who failed to com-
plete the study (15 men and 22 women). The median age and
duration of diabetes of those who completed the study were
55.0 years (IQR 44.0–65.0 years) and 8.0 years (3.5–12.5 years),
respectively. Body mass index (BMI) was 30.78 kg/m2 (27.89–
33.92). Initial levels of HbA1c, glycated albumin and fasting
glucose were 7.6% (7.00–8.55%), 17.9% (14.9–23.0%) and
125.0 mg/dL (109–168 mg/dL), respectively. A total of 38 par-
ticipants (52.05%) used insulin analogs. BMI (30.8 vs 29.0 kg/
m2, P = 0.03) and bodyweight (80.0 vs 73 kg, P = 0.026) were
statistically different between the groups who completed or
withdrew from the study. In the multivariate logistic regression
analysis investigating the predictive parameters for the discon-
tinuation of exenatide therapy, no parameter predicted the dis-
continuation of exenatide therapy in the present study
population.
Effects of Exenatide on Glycemia, Weight, Lipid Changes and
Events of Major Hypoglycemia
A signiﬁcant reduction in HbA1c level was observed over
22 weeks of exenatide b.i.d. treatment (Figure 2). The median
changes in HbA1c from baseline were –0.4% at week 8 and
-0.7% at week 22 (both P = 0.001, baseline vs all other time-
points). Overall, the HbA1c target of ≤7% was achieved in
53.4% (39/73) of participants. In addition, signiﬁcant weight
loss was also observed. The median changes in weight from
baseline were -2.3 kg at week 8 and -3.0 kg at week 22
(P < 0.001, baseline vs all other time-points). Total cholesterol
levels decreased signiﬁcantly (P < 0.001). No major hypoglyce-
mic episodes as deﬁned in the Methods section occurred during
the study period.
Improvements of 52.1, 16.4, and 31.5% were observed in
both HbA1c reduction and weight loss (group I), HbA1c only
(group II), and weight loss only (group III), respectively, in
these populations (Table 1, Figure 3). Except for use of insulin
(36.8, 41.7, and 82.6% in groups I, II, and III, respectively,
P = 0.002) and levels of fasting glucose (127.0, 138.0, and
109.0 mg/dL, respectively, P = 0.037) before study enrolment,
there were no signiﬁcant differences among the groups.
Predictive Independent Parameters to Achieve Optimal
Glycemic Control or Weight Reduction with Exenatide in
Combination with Metformin and SU
Of the 73 participants, the data of basal and stimulated insulin
and C-peptide levels within 3 months before initiation of exe-
natide were available in 50 participants. In 42 participants,
serum insulin and C-peptide levels were measured at the initi-
ation of exenatide. Measurement of baseline insulin and
C-peptide was not included in the original protocol, and it
caused these inconsistent results. Clinical and laboratory
characteristics of the participants according to their HbA1c
level reduction and weight loss responsiveness at 22 weeks
with exenatide b.i.d. are summarized in Tables S2 and S3.
Compared with the HbA1c(+) group, the HbA1c(-) group
had signiﬁcantly lower fasting glucose levels (responders vs
non-responders, 128.5 vs 109.0 mg/dL, P = 0.012), a larger
proportion of previous insulin users (38.0% vs 82.6%,
P < 0.001), higher baseline insulin levels (16.5% vs 32.4%,
P < 0.001), higher HOMA of insulin resistance (IR) values
(5.67 vs 11.3, P = 0.004), and higher HOMA of b-cell
110 patients
Exenatide b.i.d.
4-week 5 µg b.i.d. followed
by 10 µg b.i.d.
Drop out ≤ 4 wks:
10 patients (5 mcg)
4 wks: < drop out ≤ 8 wks:
25 patients (10 mcg)
Drop out: 2 patients
2nd visit at 22 weeks:
73 patients including 50 subjects with
measurement of insulin & C-peptide
1st visit at 8 weeks
75 patients
Figure 1 | Flow diagrams showing the eligibility of participants under
exenatide treatment.
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function (b) levels (73.5 vs 331.9, P < 0.001). However, the
HbA1c(-) group had signiﬁcantly lower baseline C-peptide
levels (2.31 ng/mL vs 1.36 ng/mL, P < 0.001). In addition,
there were no signiﬁcant differences in clinical characteristics
between the Wt(+) group and Wt(-) group.
We evaluated the correlation between serum delta HbA1c
levels (changes in HbA1c between baseline and week 22), and
various demographic and laboratory parameters (Table 2).
There were signiﬁcant correlations between delta HbA1c levels
and age, initial HbA1c and serum fasting glucose levels, and
several insulin secretory parameters, including HOMA-b, basal
and stimulated C-peptide levels, and baseline insulin levels.
Next, we also evaluated the correlation between serum delta
bodyweight values (weight change across 22 weeks), and vari-
ous demographic and laboratory parameters (Table 2). There
were signiﬁcant correlations between delta bodyweight values
and serum fasting glucose, HOMA-b, and baseline C-peptide
levels.
To investigate the important factors in predicting the likeli-
hood of achieving HbA1c level and weight reductions with
exenatide BID in combination with metformin and SU in obese
diabetic patients, a multiple regression analysis was carried out
(Table 3). As described previously in Table 1, the HbA1c(-)
group had a larger proportion of previous insulin users
(82.6%). This exogenous insulin administration might have
resulted in lower fasting glucose and increased insulin levels,
which are associated with signiﬁcantly higher HOMA-IR and
HOMA-b values. In this regard, we included clinically impor-
tant conventional variables and established parameters that are
signiﬁcantly correlated with delta HbA1c or bodyweight based
on Table 2, and excluded signiﬁcant factors that are inﬂuenced
by exogenous insulin therapy, such as insulin and glucose lev-
els. The analysis found C-peptide level to be a signiﬁcant inde-
pendent predictor for reduction in HbA1c levels by treatment
with exenatide in combination with SU and metformin
(b = 0.865, P = 0.018). However, there was no signiﬁcant asso-
ciation between GLP-1 analog treatment and bodyweight
reduction.
We underwent subgroup analysis according to switching
method, and included the switching method variable as an
adjusting factor. We expected that serum insulin levels would
be higher in patients who were previously treated with insulin
than in those who were treated with oral hypoglycemic agents
(OHA). The present results conﬁrmed this hypothesis, because
we found higher levels of insulin, HOMA-b and HOMA-IR,
but lower levels of C-peptide in the pre-insulin use group than
in the pre-OHA use group (Table S4A). We classiﬁed patients
according to previous drug use, as shown in Table 1. There
were no differences in C-peptide levels between the groups
(Table S4B). We also divided the participants into subgroups
based on the number of agents, and still did not ﬁnd signiﬁcant
differences in C-peptide levels between the groups (Table S4C).
Table S5 shows the results of multiple regression analysis after
adjusting for switching method. Table 3 and Table S5 showed
consistent results.
Regarding the possible correlation between pre-exenatide
therapy with OHA, and HbA1c and bodyweight reduction, 35
participants (47.95%) used OHA. Except for two participants
(2.7%) who were taking both metformin and pioglitazone, par-
ticipants taking OHA were dependent on insulin secretagogue,
such as SU and DPP-4 inhibitor. To further investigate the pre-
dicting factors for bodyweight reduction without improvement
of glycemic control, the 73 participants were classiﬁed into
group III and the remaining groups (group I and II). The
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Figure 2 | Changes in (a) glycated hemoglobin (HbA1c) level,
(b) weight and (c) total cholesterol levels over 22 weeks of exenatide
treatment. *P < 0.05 versus baseline.
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Table 1 | Changes in anthropometric and biochemical parameters of the study population over 22 weeks of treatment with a exenatide,
metformin, sulfonylurea combination
Characteristics Response at 22 weeks later P
Group I Group II Group III
HbA1c (+), Wt (+), n = 38 HbA1c (+), Wt (-), n = 12 HbA1c (-), Wt (+), n = 23
Median IQR Median IQR Median IQR
Baseline
Age (years) 55.5 [46.8–64.8] 58.5 [54.3–67.0] 47.0 [36.0–65.0] 0.187
Sex (male %) 13,34.2% 4 (33.3%) 6 (26.1%) 0.794
Durationo of
diabetes (years)
8.0 [3.5–12.8] 8.5 [3.0–15.5] 7.0 [5.0–13.0] 0.995
Previous treatment
(insulin, %)
14 (36.8%) 5 (41.7%) 19 (82.6%) 0.002
Insulin dose 69.0 [43.0–93.0] 78.0 [52.0–95.0] 46.0 [36.0–87.0]
BIA + OHA 14 (36.8%) 4 (33.3%) 15 (65.2%)
LLA + OHA 1 (8.3%) 4 (17.4%)
Previous OHA treatment
metf + SU+/-a-GI 13 (34.2%) 5 (41.7%) 2 (8.7%)
metf + piog 2 (5.3%)
metf + DPP4-l 4 (10.5%)
metf + SU + DPP4-I 1 (2.6%) 2 (16.7%)
piog + SU +/- a-GI 3 (7.9%) 2 (8.7%)
piog + SU + metf 1 (2.6%)
Weight (kg) 79.5 [71.9–91.5] 77.8 [71.5–96.1] 80.0 [73.0–88.9] 0.972
BMI (kg/m2) 30.6 [27.3–33.4] 30.6 [27.0–36.0] 30.8 [29.0–34.6] 0.734
SBP (mmHg) 134.0 [125.5–143.0] 139.0 [124.0–145.0] 131.0 [125.0–143.0] 0.592
DBP (mmHg) 76.5 [66.8–88.0] 81.5 [71.0–87.5] 78.0 [73.0–85.0] 0.715
HbA1c (%) 7.6 [–7.0–9.0] 7.9 [6.9–8.5] 7.5 [7.0–8.4] 0.914
GA (%) 17.4 [14.9–23.0] 17.7 [13.9–22.0] 18.1 [14.6–20.6] 0.651
Glucose (mg/dL) 127.0 [114.5–172.8] 138.0 [120.5–165.3] 109.0 [92.0–147.0] 0.037
BUN (mg/dL) 14.6 [12.1–21.1] 14.0 [12.2–16.4] 13.1 [10.8–18.2] 0.488
Creatinine (mg/dL) 0.9 [0.7–1.0] 0.8 [0.7–0.9] 0.8 [0.7–1.0] 0.540
T.chol (mg/dL) 174.0 [152.8–200.5] 157.5 [143.0–200.0] 160.0 [141.0–175.0] 0.230
TG (mg/dL) 146.5 [112.0–215.8] 167.5 [105.8–291.5] 139.0 [101.0–180.0] 0.354
HDL (mg/dL) 45.0 [38.8–51.3] 41.0 [38.3–53.3] 44.0 [39.0–54.0] 0.876
LDL (mg/dL) 93.5 [69.2–122.7] 74.2 [59.6–107.1] 81.4 [67.6–100.6] 0.362
2nd visit (after 8 weeks)
Weight (kg) 77.4 [69.1–88.0] 79.0 [71.7–98.1] 76.5 [69.9–85.0] 0.597
BMI (kg/m2) 30.3 [26.7–33.2] 30.4 [27.6–36.4] 30.5 [26.5–33.3] 0.635
HBA1c (%) 6.8 [6.2–7.4] 7.3 [6.9–8.0] 7.9 [7.2–10.0] 0.002
GA (%) 14.0 [12.0–17.5] 17.0 [14.0–18.0] 18.5 [14.9–23.9] 0.011
Glucose (mg/dL) 115.0 [98.8–136.3] 151.5 [118.3–168.0] 161.0 [118.0–206.0] 0.002
T.chol (mg/dL) 152.5 [140.0–179.5] 155.0 [132.5–174.3] 138.0 [123.0–195.0] 0.717
TG (mg/dL) 140.5 [100.8–190.5] 170.0 [114.8–222.8] 140.0 [101.0–288.0] 0.370
HDL (mg/dL) 41.0 [36.0–46.0] 40.0 [31.5–49.0] 39.0 [31.0–50.0] 0.907
LDL (mg/dL) 80.3 [59.0–102.1] 83.5 [55.6–101.9] 66.2 [39.0–102.8] 0.592
3rd visit (after 22 weeks)
Weight (kg) 75.7 [66.9–86.7 ] 80.4 [72.8–98.5] 74.8 [66.3–81.8] 0.269
BMI (kg/m2) 28.8 [25.7–32.7] 31.0 [27.4–36.1] 29.3 [26.4–32.0] 0.282
HBA1c (%) 6.6 [6.1–7.2] 6.9 [6.6–7.6] 9.1 [7.4–10.7] <0.001
GA (%) 15.0 [12.5–17.5] 14.0 [13.0–22.0] 22.0 [16.0–26.8] 0.001
Glucose (mg/dL) 110.0 [99.8–136.3] 129.0 [108.5–145.5] 174.0 [145.0–232.0] <0.001
T.chol (mg/dL) 160.0 [133.8–190.3] 155.5 [129.3–188.5] 144.0 [117.0–184.0] 0.241
TG (mg/dL) 147.5 [107.8–211.8] 168.5 [111.3–245.8] 140.0 [105.0–176.0] 0.562
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baseline C-peptide (remaining group vs group III, 2.30 vs
1.36 ng/mL, P < 0.001), baseline insulin (16.5 vs 32.4 lU/mL,
P < 0.001), glucose (139 vs 109 mg/dL, P = 0.012), HOMA-b
(73.5 vs 331.9, P < 0.001) and HOMA-IR (5.67 vs 11.3,
P = 0.004) were signiﬁcantly different between the remaining
groups (I and II) and group III. Group III tended to be youn-
ger than the remaining group (59.0 vs 54.0 years, P = 0.084).
During the multivariate logistic regression analysis, weight
reduction without improvement of glycemic control was used
as a dependent variable, and conventional variables and
established parameters that are signiﬁcantly correlated with
delta weight based on Table 2. such as age, HbA1c, HOMA-b,
HOMA-IR, previous treatment of insulin and baseline C-pep-
tide, were entered as independent factors. To avoid the collin-
earity with HOMA values, baseline insulin level was not
included. We found that the baseline C-peptide level was also a
signiﬁcant independent predictor for reduction in bodyweight
without improvement of glycemic control by treatment with
exenatide in combination with SU and metformin (b = -1.348,
P = 0.018).
DISCUSSION
Secretory b-cell dysfunction is a stronger contributing factor
than insulin resistance in the development and aggravation of
type 2 diabetes, and is known as a traditional characteristic of
Korean type 2 diabetics1,6,7. Recent epidemiological data have
also shown that Korean populations with BMI over 25 kg/m2
had been more prone to morbidity and mortality risk8,9. It is
known that Asians generally have a slighter body build and less
muscle mass than Caucasians. The World Health Organization
recommends that cut-off values in the deﬁnition of overweight
and obesity should be lower for Asian than for Western popu-
Table 1 (Continued)
Characteristics Response at 22 weeks later P
Group I Group II Group III
HbA1c (+), Wt (+), n = 38 HbA1c (+), Wt (-), n = 12 HbA1c (-), Wt (+), n = 23
Median IQR Median IQR Median IQR
HDL (mg/dL) 39.5 [35.8–42.0] 39.0 [34.5–53.8] 42.0 [33.0–48.0] 0.727
LDL (mg/dL) 79.5 [63.1–104.5] 72.9 [54.5–115.9] 70.2 [58.6–110.2] 0.909
Non-normal distribution expressed by median and interquartile range (IQR). a-GI, alpha-glucosidase inhibitor; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; BIA, biphasic insulin analog; BMI, body mass index; BUN, blood urine nitrogen; DBP, diastolic blood pressure; DPP4-I
dipeptidyl peptidase 4 inhibitor; eGFR: estimated glomerular filtration rate; GA, glycated albumin; HbA1c, glycated hemoglobin; HbA1c (+), patients
who had improved glycated hemoglobin levels; HDL, high-density lipiprotein cholesterol; HLAA, long acting insulin analog; HOMA-b, homeostasis
model assessment for beta-cell function; HOMA-IR, homeostasis model assessment for insulin resistance; LDL, low-density lipoprotein cholesterol;
metf, metformin; piog, pioglitazone; SU, sulphonylurea; T.chol, total cholesterol; TG, triglyceride; WH ratio, waist-to-hip ratio;Wt (+), patients who had
a weight reduction.
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Figure 3 | Efficacy of exenatide for glycated hemoglobin (HbA1c) level and weight changes over 22 weeks of combination treatment with
exenatide, sulphonylurea and metformin. Group I, both HbA1c and weight responders; group II, HbA1c only responders; group III, weight only
responders.
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lations. In this regard, the BMI categories in Korea are different
from typical North American stratiﬁcation. Recent epidemiolog-
ical data have shown that the prevalence of obesity (BMI
≥25 kg/m2), severe obesity (BMI ≥30 kg/m2) and metabolic
syndrome have rapidly increased in the past few decades in
Korea8. Considering the pathophysiological characteristics and
epidemiological trends of type 2 diabetes in the Korean popula-
tion, we hypothesized that patients who are more obese and
have reserved b-cell function would be more likely to respond
to GLP-1 analog therapy. Based on this hypothesis, our atten-
tion was focused on investigating the expected tolerability/safety
and effectiveness, as well as the predictive characteristics of
patients who could achieve greater glycemic control and weight
reduction with a GLP-1 analog, by comparing indices related to
b-cell function and insulin resistance with clinically important
conventional parameters, such as duration of diabetes, BMI,
pre-study medications and so on.
The present clinical study of obese Korean type 2 diabetics
treated with exenatide b.i.d. with a combination of metformin
and SU for up to 22 weeks showed two main ﬁndings. First,
the study presents data on the tolerability, adverse effects and
effectiveness of exenatide. Of 110 participants, 35 participants
(31.9%) failed to continue on exenatide within 8 weeks (10 par-
ticipants within 4 weeks, 25 between 5 and 8 weeks) of initiat-
ing exenatide b.i.d. treatment, which is a higher failure rate
than previous reports carried out in Caucasian populations10–12.
Of the 37 participants who withdrew from the study, the rea-
sons for withdrawal included one participant (3.0%) with aggra-
vated hyperglycemia and seven participants (21.2%) who were
to reluctant to receive the exenatide injection. The remaining
participants mainly withdrew because of gastrointestinal side-
effects, such as nausea, vomiting and diarrhoea, or injection
repulsion. Based on this ﬁnding, caution should be exercised in
treatment with exenatide in patients targeting intensive glyce-
mic control; special attention needs to be paid to the patients’
tolerability. However, no additional patients discontinued exe-
natide after 8 weeks of treatment. Although participants who
discontinued the drug were signiﬁcantly less obese than partici-
Table 2 | Correlation between delta HbA1c over 22 weeks and clinical
and laboratory parameters
Change of HbA1 c Change of weight
Correlation
coefficient
P-value Correlation
coefficient
P-value
Age (years) 0.263 0.024 0.001 0.996
DM duration (years) 0.067 0.576 0.068 0.568
Height (cm) -0.087 0.464 -0.117 0.325
Weight (kg) -0.062 0.601 -0.005 0.967
BMI (kg/m2) -0.023 0.850 0.053 0.658
Waist (cm) -0.014 0.905 0.075 0.530
Hip (cm) -0.049 0.678 0.096 0.419
WH ratio 0.050 0.672 -0.069 0.563
HbA1c (%) 0.256 0.029 -0.157 0.186
GA (%) 0.224 0.059 -0.053 0.659
Glucose (mg/dL) 0.417 <0.001 -0.253 0.031
Creatinine (mg/dL) 0.015 0.900 -0.071 0.550
T.cholesterol (mg/dL) 0.197 0.095 -0.001 0.996
TG (mg/dL) 0.034 0.775 -0.116 0.327
HDL (mg/dL) 0.031 0.792 0.092 0.441
LDL (mg/dL) 0.150 0.206 0.074 0.534
HOMA-b -0.660 <0.001 0.369 0.008
HOMA-IR -0.271 0.057 0.095 0.511
Baseline
C-peptide (ng/mL)
0.497 <0.001 -0.280 0.047
Simulated
C-peptide (ng/mL)
0.284 0.044 -0.204 0.151
Baseline
insulin (lU/mL)
-0.519 <0.001 0.206 0.151
Stimulated
insulin (uU/mL)
-0.175 0.224 0.072 0.617
BMI, body mass index; DM, diabetes mellitus; GA, glycated albumin;
HbA1c, glycated hemoglobin; HDL, high-density lipiprotein cholesterol;
HOMA-b, homeostasis model assessment for beta-cell function;
HOMA-IR, homeostasis model assessment for insulin resistance; LDL,
low-density lipoprotein cholesterol; T.cholesterol, total cholesterol; TG,
triglyceride; WH ratio, waist-to-hip ratio.
Table 3 | Multivariable regression analysis between other glycaemic inidices and change of HbAlc Level as dependent variables, over 22 weeks
Unstandardized coefficients P-value 95.0% Confidence interval
B Std. error Lower Upper
Age 0.024 0.018 0.180 -0.012 0.060
HbA1c 0.149 0.132 0.265 -0.117 0.414
Previeous insulin use -0.246 0.585 0.676 -1.427 0.934
Baseline C-peptide 0.865 0.353 0.018 0.153 1.577
Stimulated C-peptide -0.145 0.138 0.298 -0.423 0.133
HOMA-b 0.000 0.000 0.802 -0.001 0.001
HOMA-IR -0.033 0.018 0.071 -0.070 0.003
HbA1c, glycated hemoglobin; HOMA- b, homeostasis model assessment for beta-cell function; HOMA-IR, homeostasis model assessment for insulin
resistance.
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pants who continued, no parameter predicted the discontinua-
tion of exenatide therapy in the present study. In this regard,
further studies targeting patients who tolerate exenatide well
would be interesting and necessary to introduce a GLP-1 ana-
log into clinical practice. Regarding hypoglycemia, no major
hypoglycemic episodes were observed in the present study, even
though SUs were used in combination. The occurrence rate of
hypoglycemia in Korean diabetes patients treated with exenatide
was different from previous Diabetes Management for Improv-
ing Glucose Outcomes (AMIGO) clinical trials11–13. The hypo-
glycemia occurrence rate was lower in the present study than
in the AMIGO studies. It might have been caused by a higher
dropout rate than the AMIGO studies. Improvement in HbA1c
levels and weight loss could be observed during the study per-
iod. Similar to a previous short-term study of exenatide b.i.d.
used with either metformin, SU or thiazolinedione, and a com-
bination of metformin and SU in a Caucasian population10–13,
68.5% of the participants in the present study achieved a
decrease in HbA1c. Despite the lack of a speciﬁc diet and exer-
cise program, steady weight reduction (80.0 kg at baseline,
77.7 kg at the ﬁrst visit and 77.0 kg at the second visit) during
the 22-week treatment period was observed in the present
study. Of the participants who completed the study, 52.1%
(n = 38) lost weight and improved their HbA1c levels.
A HbA1c level ≤7% was achieved in 53.4% of participants who
completed the study. However, the degree of bodyweight
change was not different between those who achieved and did
not achieve a HbA1c level ≤7%. In this regard, weight reduc-
tion and HbA1c reduction appear to be mutually exclusive in
treatment with a GLP-1 analog. With respect to lipid proﬁles,
exenatide treatment was associated with a signiﬁcant reduction
in total cholesterol levels.
Second, the present study tried to provide the predictive
characteristics of participants who would achieve a desirable
glycemic index and bodyweight reduction. To appropriately
evaluate b-cell function, we used two speciﬁc indices that reﬂect
insulin secretory capacity in the context of ambient insulin
resistance. Among various factors assessed in the present study,
age, high glucose parameters (HbA1c, fasting glucose) and
b-cell secretory parameters (HOMA-b, fasting and stimulated
C-peptide levels, fasting insulin level) were signiﬁcantly associ-
ated with a greater reduction in HbA1c levels with exenatide
b.i.d. in combination with both SU and metformin in obese
Korean type 2 diabetes patients, as seen in Table 2. In addition,
insulin na€ıvete was signiﬁcantly associated with HbA1c reduc-
tion responsiveness in obese Korean type 2 diabetics. This
implies that clinical factors are still important in predicting
responsiveness to GLP-1 analogs in obese patients with type 2
diabetes. In the present study, delta HbA1c level was negatively
associated with HOMA-b and insulin levels, but was positively
associated with C-peptide levels. These conﬂicting data might
have been inﬂuenced by higher usage of exogenous insulin ana-
logs in the HbA1c(-)group. In this regard, we excluded insulin
and glucose levels that might be inﬂuenced by exogenous insu-
lin treatment in multiple regression analysis. Contrary to a pre-
vious efﬁcacy report on the association of greater HbA1c
reduction with insulin sensitivity (HOMA-S) in a Caucasian
population14, insulin secretory function of C-peptide was associ-
ated with an adequate response of patients to GLP-1 analog
therapy. However, HOMA-IR, as an independent variable,
showed a tendency to inﬂuence the improvements of HbA1c in
Korean type 2 diabetes patients treated with exenatide. Previous
studies have shown that the reduced incretin effect itself and
incretin receptor expression are not the primary events in the
development of type 2 diabetes, but rather a consequence of
the hyperglycemic state15,16. This phenomenon could be associ-
ated with suppressed insulin secretory function in type 2 diabe-
tes. In summary, intact insulin secretory function accompanied
with less use of exogenous insulin was the predictive parameter
for achieving a desirable glycaemic index in Korean patients
with type 2 diabetes.
Several recent studies including Korean type 2 diabetics have
shown that treatment with GLP-1 analogs and DPP-4 inhibi-
tors enhances pancreatic b-cell function resulting in HbA1c
level reductions17–19. Based on these results, we suggest that
the addition of a GLP-1 analog might be another option in
poorly-controlled Korean diabetic patients who had experienced
pancreatic islet failure related to the main pathophysiological
mechanism of development and aggravation in type 2 diabetes.
The present study had some limitations. First, this study was
designed as an uncontrolled, open-label, single center study,
which limits its applicability and clinical relevance to the greater
Korean population and to broader clinical practice. Second, not
all participants were available for the evaluation of b-cell func-
tion and insulin resistance, which could limit the interpretation
of predictive characteristics that might apply well to those who
were responders to the GLP-1 analog. Third, insulin should
have been discontinued before measuring insulin level to
exclude exogenous insulin effect, which might confound the
interpretation of insulin levels and HOMA values. However,
this is the ﬁrst well-designed and documented study in the
analysis and interpretation of GLP-1 analog targeting Korean
patients.
In conclusion, exenatide BID in combination with both met-
formin and SU was an effective option for obese Korean
patients with suboptimally controlled type 2 diabetes. Notably,
clinical and laboratory parameters, such as insulin na€ıvete, and
preserved b-cell function, such as C-peptide levels, should be
taken into consideration as important factors in the choice of
GLP-1 analog when predicting GLP-1 analog response. Further
studies are essential to investigate patients who tolerate the
GLP-1 analog well.
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Additional Supporting Information may be found in the online version of this article:
Table S1 | Anthropometric and clinical characteristics of participants who continued or discontinued the drug.
Table S2 | Anthropometric and clinical characteristics according to glycated hemoglobin improvement after 22 weeks.
Table S3 | Anthropometric and clinical characteristics according to weight improvement over 22 weeks.
Table S4A | HOMA index and C-peptide levels according to previous treatment with insulin or oral hypoglycemic agents.
Table S4B | HOMA index and C-peptide levels according to type of previous drug used.
Table S4C | HOMA index and C-peptide levels according to switching method.
Table S5A | Multivariable regression analysis of other glycemic indices in which the dependent variable is the change in glycated
hemoglobin during 22 weeks after adjusting for switching method.
Table S5B | Multivariable regression analysis of other glycemic indices in which the dependent variable is weight change during
22 weeks after adjusting for switching method.
Methods S1| Drug switching protocol.
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